Last thought for the day - the more I follow all the Drug news, the more I realize that the FDA may not be corrupt. All these drugs, to Nader’s point on a recent proactive, are simply hitting their clinical endpoints.

The problem is that the more money and brand recognition you have, it seems the easier it is to game the FDA’s system. Either by your ability to design (or change) a trial in such a way to make an endpoint a slam dunk or by getting a large N from folks who trust the brand just because they’ve heard of the big pharma company on commercials or because the doc is pushing it.

Chicken or egg. Once CYDY is in the door the game can change quickly on each subsequent trial and we will get economies of scale (trial design expertise, talent pool enhancement, brand recognition, drug name recognition, revenues, large N, on radar, etc). Snowball effect.

Adjust your time horizon and note the forward progress. Short term pain for long term gain is the path to success in virtually every endeavor ever undertaken by anyone.